bioRxivBiochemistry
Selective inhibition reveals the regulatory function of DYRK2 in protein synthesis and calcium entry
X. Lei, T. Wei, J. Wang, R. Liang, W. Chen, A. He, Y. Du, W. Zhou, Z. Zhang, M. Ma, J. Lu, X. Guo, X. Chen, R. Tian, J. Xiao
Abstract
The dual-specificity tyrosine phosphorylation-regulated kinase DYRK2 has emerged as a key regulator of cellular processes such as proteasome-mediated protein degradation. To gain further insights into its function, we took a chemical biology approach and developed C17, a potent small-molecule DYRK2 inhibitor, through multiple rounds of structure-based optimization guided by a number of co-crystallized structures. C17 displayed an effect on DYRK2 at a single-digit nanomolar IC50 and showed outstanding selectivity for the human kinome containing 467 other human kinases. Using C17 as a chemical probe, we further performed quantitative phosphoproteomic assays and identified several novel DYRK2 targets, including eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) and stromal interaction molecule 1 (STIM1). DYRK2 phosphorylated 4E-BP1 at multiple sites, and the combined treatment of C17 with AKT and MEK inhibitors showed synergistic 4E-BP1 phosphorylation suppression. The phosphorylation of STIM1 by DYRK2 substantially increased the interaction of STIM1 with the ORAI1 channel, and C17 impeded the store-operated calcium entry process. Collectively, these studies further expand our understanding of DYRK2 and provide a valuable tool to further pinpoint its biological function.
- organism: human
- assay: proteomics
- research focus: cell signaling & trafficking
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Phosphoproteomics identifies the DYRK1B protein kinase as a regulator of processing bodies
Anne L. Ashford, Suzan Ber, … Simon J. Cook·Journal of Cell SciencePeer-reviewed·Aug 13, 2026
- Novel small-molecule inhibitors of the protein kinase DYRK: Potential Therapeutic candidates in cancer
Prabhadevi Venkataramani, Elad Elkayam, … Nicholas K. Tonks·bioRxiv·Nov 5, 2025
- Loss of the DYRK1A protein kinase results in reduction of ribosomal protein genes expression, ribosome mass and translation defects
Chiara Di Vona, Laura Barba‐Moreno, … Susana de la Luna·bioRxiv·Jan 21, 2021
- Quantitative phosphoproteomics reveals regulatory state dependent efficacy of chemical Cdk1 inhibition and distinct Cdk5 complexes as novel Wee1 substrates
A. V. Grassetti, R. Hards, S. A. Gerber·bioRxiv·Sep 27, 2021
- ERK inhibits Cic repressor function via multisite phosphorylation
Sayantanee Paul, Khandan Ilkhani, … Alexey N. Veraksa·bioRxiv·May 14, 2024
- Pharmacologic Inhibition of DYRK1A Results in MYC Hyperactivation and ERK Hyperphosphorylation rendering KMT2A-R ALL Cells Sensitive to BCL2 Inhibition
C. Hurtz, V. S. S. A. Ayyadevara, … S. K. Tasian·bioRxiv·Oct 2, 2022